Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United TherapeuticsUTHR +1.15%89 EV-to-OCF is 11.86 as of Aug. 09, 2026, which is 26% above its 10-year median of 9.45. GuruFocus rates UTHR with a GF Score™ of 89/100 and a GF Value™ of $427.22 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, United Therapeutics ranks worse than 52.58% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, United Therapeutics's Enterprise Value is $19,993 Mil.
United Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $1,685 Mil. Therefore, United Therapeutics's EV-to-OCF for today is 11.86.
The historical rank and industry rank for United Therapeutics's EV-to-OCF or its related term are showing as below:
UTHR'
s EV-to-OCF Range Over the Past 10 Years
Min: -38.04 Med: 9.45 Max: 16.39
Current: 11.86
During the past 13 years, the highest EV-to-OCF of United Therapeutics was 16.39. The lowest was -38.04. And the median was 9.45.
UTHR's EV-to-OCF is ranked worse than 52.58% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.06
vs UTHR: 11.86
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Therapeutics (NAS:UTHR) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Therapeutics's PE Ratio (TTM) for today is calculated as:
United Therapeutics's share price for today is $538.91.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
United Therapeutics EV-to-OCF Related Terms
United Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for United Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-OCF falls into.
United Therapeutics's current Enterprise Value is $19,993 Mil.
United Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,685 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a EV-to-OCF of 11.86 as of Aug. 09, 2026. This is 26% above median its historical median of 9.45. According to the industry distribution chart, United Therapeutics ranks #529 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 52.6%.
Is United Therapeutics' EV-to-OCF too high?
United Therapeutics' current EV-to-OCF of 11.86 is 26% above median its 10-year median of 9.45. The Drug Manufacturers industry median EV-to-OCF is 11.06. United Therapeutics' value of 11.86 is 7.2% above this industry median. Based on the distribution chart, United Therapeutics ranks #529 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Therapeutics has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EV-to-OCF compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #529 out of 1006 companies for EV-to-OCF. This places United Therapeutics in the lower half of its industry. The industry median EV-to-OCF is 11.06. United Therapeutics' value of 11.86 is 7.2% above this benchmark. While the company's 10-year median is 9.45 vs. the industry median of 11.06, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current EV-to-OCF of 11.86 is 7.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current EV-to-OCF is 11.86, which is 26% above median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Modestly Overvalued. The stock's GF Value™ is $427.22, compared to a current price of $538.91 — trading 26.1% above its estimated fair value. The current EV-to-OCF is 11.86, which is 26% above median its 10-year median of 9.45 and 7.2% above the Drug Manufacturers industry median of 11.06. United Therapeutics' overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For United Therapeutics (UTHR), the current EV-to-OCF is 11.86 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $538.91 is trading 26.1% above its estimated GF Value™ of $427.22.
GuruFocus considers United Therapeutics to be Modestly Overvalued.
Key valuation signals for UTHR:
EV-to-OCF: 11.86 (26% above median its 10-year median of 9.45)
GF Value™: $427.22 vs. price of $538.91 (26.1% above fair value)
Industry Position: 7.2% above the Drug Manufacturers median (#529 of 1006)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
89GF Score
Get the complete analysis for UTHR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
